Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Lancet Haematol.(2019).
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.Am J Hematol.(2019).
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Cancer.(2016).
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.Br J Haematol.(2015).
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.Lancet Haematol2, e186-93.(2015).
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.Jama Oncol.(2015).
Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.Blood.(2013).